Previous 10 | Next 10 |
home / stock / bcli / bcli articles
NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ:BCLI) shareholders: ...
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, ...
NEW YORK, Nov. 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Br...
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, ...
NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm C...
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds invest...
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons...
ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed aga...
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action laws...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial PR Newswire NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell thera...